TOP - July 2020, Vol 13, No 4

The July issue of The Oncology Pharmacist (TOP) is filled with important news and insights for today’s oncology pharmacist.
The first “off-the-shelf” chimeric antigen receptor (CAR) T-cell platform targeting CD7 induced a complete response (CR) with no minimal residual disease (MRD) in 4 of the first 5 adults with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) who received treatment with the universal CAR T-cell therapy currently labeled GC027.
In January 2020, the American Society of Clinical Oncology (ASCO) issued a major update to its Patient-Centered Oncology Payment (PCOP) model, an alternative payment model “designed to support transformation in cancer care delivery and reimbursement while ensuring that patients with cancer have access to high-quality, high-value care,” according to a statement from ASCO.
Every infusion center needs to understand what resources it has (or will have) available at any given time during any particular day—whether it is open chairs, treating registered nurses, or pharmacy staff.
San Francisco, CA—Today, patients who receive stereotactic body radiation therapy (SBRT) for intermediate- or high-risk localized prostate cancer are not receiving concurrent androgen-deprivation therapy (ADT), despite national guideline recommendations that support the concurrent use of ADT with radiation therapy.
No improvement in survival or in any key secondary end point was observed when the checkpoint inhibitor atezolizumab (Tecentriq) was added to enzalutamide (Xtandi) for the treatment of metastatic castration-resistant prostate cancer (CRPC) in the phase 3 IMbassador250 trial.
San Francisco, CA—Although there is a biological rationale that supports the “abscopal” effects of radiation therapy plus checkpoint immunotherapy in fighting cancer, this combination showed mixed results and no robust effects in patients with metastatic renal-cell carcinoma (RCC), according to results of 2 preliminary studies presented at the 2020 Genitourinary Cancers Symposium.
San Antonio, TX—Although capecitabine (Xeloda) is approved for metasta­tic breast cancer, it is not clear whether it should be used in early breast cancer, and its optimal role remains to be established.
At the 2020 virtual American Association for Cancer Research (AACR) annual meeting, part I, a team of oncologists from different COVID-19 hotspots around the world gave a snapshot of wisdom gleaned from their experience thus far.
This section provides a brief overview of new cancer drugs or new indications approved by the FDA between May 26 and June 15, 2020.
Page 1 of 2
Results 1 - 10 of 19